LOS ANGELES--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced results of the company-sponsored PROMISE Study, demonstrating ...

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED ...

Launches Indigo® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical Officer Lightning™ 12 – Intelligent ...

Penumbra, Inc. PEN recently received FDA clearance for the RED 62 Reperfusion Catheter. Following this regulatory go-ahead, the company has also initiated commercial availability of the catheter ...

Pulmonary embolism, or PE, is a deadly condition causing blood clots within a patient’s lungs that has grown in prevalence during the COVID-19 pandemic. The Indigo Aspiration System with Lightning 12 ...

Penumbra ($PEN), one of the top devicemaker IPOs last year, unveiled its latest thrombectomy product to the U.S. market. Dubbed the ACE 68 Reperfusion Catheter, the ...

BOSTON, Mass. - July 27, 2016 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, ...

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced initial INSIGHT Registry data showing Penumbra’s RED ® reperfusion catheters were successful in ...

Neurovascular device maker Penumbra will ring the opening bell on the New York Stock Exchange today, as it kicks off life as a public company with an upsized $120 million IPO--one of the device ...

Penumbra, Inc. PEN is expected to report fourth-quarter 2017 results on Feb 27, after market close. Last quarter, the company posted a positive earnings surprise of 114.3%. Moreover, Penumbra has ...

Launches Indigo ® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical ...